Multiple myeloma

Cancer Control

Volumn 8, Issue 6 SUPPL., 2001, Pages 78-87

  Traynor, A E ^a   Noga, S J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CISPLATIN; CLADRIBINE; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUDARABINE; FUROSEMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; MELPHALAN; NITROSOUREA DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE DERIVATIVE; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; STEROID; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

AMYLOIDOSIS; ANEMIA; BLOOD VISCOSITY; BONE DISEASE; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; HUMAN; HYDRATION; HYPERCALCEMIA; INFECTION; KIDNEY DISEASE; MULTIPLE MYELOMA; PLASMACYTOMA; PLASMAPHERESIS; PRACTICE GUIDELINE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PROGNOSIS; SALVAGE THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMACYTOMA; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035185149     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Cancer Statistics, 2001
2. Multiple myeloma: Review of 869 cases
3. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials
4. The treatment of multiple myeloma
5. Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies
6. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
7. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
8. Antitumor activity of thalidomide in refractory multiple myeloma
9. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
10. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system
11. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma
12. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants
13. A new staging system for multiple myeloma based on the number of S-phase plasma cells
14. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone
15. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
16. Long-term survival in multiple myeloma
17. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia
18. Alternate day oral prednisone maintenance therapy improves progressionfree survival and overall survival in multiple myeloma patients
19. Thalidomide in the treatment of relapsed multiple myeloma
20. Who benefits from high-dose therapy for multiple myeloma?
21. Intensive treatment strategies in multiple myeloma
22. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
23. Curability of solitary bone plasmacytoma
24. Radiotherapy in the management of plasma cell tumors
25. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone
26. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
27. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome
28. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective casematched study from the European Group for Blood and Marrow Transplantation
29. Graft- versus-myeloma effect: Proof of principle
30. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
31. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
32. The role of autologous hematopoietic stem cell transplantation in multiple myeloma
33. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
34. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
35. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
36. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein
37. Erythropoietin treatment of anemia associated with multiple myeloma
38. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multi-center study
39. Waldenstrom's macroglobulinemia
40. Laboratory investigation of myeloma
41. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine
42. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine
43. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
44. The systemic amyloidoses
45. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
46. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients